Pharmaceutical & Regulatory Affairs
The £180M program. The 18-month delay. The timeline that explained it.
When a pharmaceutical program timeline contradicts regulatory submissions and trial data commitments, the gap between what was submitted to the regulator and what actually happened is where compliance exposure lives. We reconstruct the true program chronology so you see exactly what the regulatory record shows — before the audit.
Reconstruction Timeline
Regulatory submission filed
Programme timeline states Phase 2 completion by Month 12
FDA meeting minutes: timeline confirmed
Regulator acknowledges stated timeline and commits to review schedule
Phase 2 enrollment challenges emerge
Internal communications note recruitment delays; not communicated to regulator
Phase 2 extension notification sent
Programme now delayed 6 months — communications show internal knowledge of delay from Month 6
Phase 2 completed — final analysis ongoing
Timeline now 6 months behind regulatory submission; delay duration known since Month 6
Regulatory inspection initiated
FDA requests timeline documentation; delay concealment identified
The Contradiction
One of these is wrong — and the longer it stays invisible, the more it costs.
What was reported
Submission stated Phase 2 completion by Month 12
FDA minutes confirmed timeline
Internal emails show Month 6 awareness of delay
Extension notification sent Month 12 — 6 months late
What actually happened
Actual Phase 2 completion at Month 18
Delay known internally from Month 6
Regulator not notified until Month 12
Timeline contradiction pattern documented
Commercial Impact
£28M regulatory non-compliance exposure
Programme integrity questioned
Potential submission fraud investigation
What would you do?
Without reconstruction
Regulatory submissions accepted at face value
Internal challenges communicated reactively when unavoidable
Timeline discrepancies discovered during regulatory inspection
Gap between submission and actual delivery not proactively documented
Regulatory risk unquantified until FDA raises questions
With RippleXn
Regulatory submissions cross-checked against internal timelines pre-submission
Foreseeable challenges and delays documented before regulator notification
Actual delivery timeline compared to commitments; discrepancies resolved pre-inspection
Timeline gaps identified and mitigating communication prepared proactively
Regulatory compliance posture strengthened before FDA inquiry
The invisible problem
The regulatory gap that hides in the timeline
Regulatory submissions are based on timelines and commitments. But when the internal timeline contradicts the submission, when regulatory commitments are made based on optimistic assumptions, and when challenges are known internally but not disclosed promptly — the gap between what the regulator believes and what actually happens is where compliance exposure lives.
Programme timelines in regulatory submissions differ from actual delivery
Regulatory commitments are made without margin for foreseeable challenges
Internal timeline delays are known before regulatory notification occurs
Manufacturing readiness assertions are not supported by actual qualification status
Data delivery commitments are missed when internal problems are not escalated
How we reconstruct regulatory programme fidelity
Ingest
Upload regulatory submissions, commitments, internal timelines, and correspondence
Map
Regulatory timeline extracted from submissions and mapped against internal development timeline
Compare
Submission dates and commitments cross-checked against internal correspondence and actual milestones
Surface
Timeline gaps, commitment vs delivery mismatches, and disclosure timing identified
Quantify
Regulatory compliance exposure calculated; proactive disclosure options prepared
The commercial reality
Know what your regulatory record actually says before the FDA does
Regulatory compliance is not about perfect execution. It is about transparent disclosure and timeline fidelity. We show you the gaps before the audit.
Ready to apply this to your situation?
Get a personalized assessment. Start with a £149 diagnostic check or dive straight into a full reconstruction.
Click here to find out moreEnsure regulatory submission fidelity before inspection
Upload your regulatory submissions, internal timelines, and correspondence. We reconstruct the full programme timeline and surface commitment vs delivery gaps before FDA inspection.